



October 28, 2024

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Outcome of Board Meeting
Ref: Regulation 30 and 33 of SEBI (LODR)
Regulations, 2015

We wish to inform you that Board of Directors at their meeting held today i.e. **Monday, October 28, 2024** inter-alia considered and approved the following:

- The Audited Financial Results of the Company (Standalone and Consolidated) for the quarter and half year ended September 30, 2024, basis recommendation of the Audit Committee;
- Auditor's Report on the Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024.

The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 03:50 p.m.

The above information is also available on the website of the Company:
www.aartipharmalabs.com

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED


NIKHIL NATU
COMPANY SECRETARY
ICSI M. NO. A27738

Encl: a/a


AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED							
Standalone Audited Financial Results for the Quarter & Half year ended 30th September, 2024							
(Rs in Lakhs except EPS)							
Sr. No.	Particulars	Standalone Results					
		3 Months Ended			6 Months Ended		Year Ended
		30th Sept 2024 (Audited)	30th June 2024 (Audited)	30th Sept 2023 (Audited)	30th Sept 2024 (Audited)	30th Sept 2023 (Audited)	31st Mar 2024 (Audited)
1	INCOME						
	a) Revenue from Operations (Net)	37,729.43	39,348.65	35,614.28	77,078.08	71,428.73	150,213.20
	b) Other Income	294.66	211.29	-	505.95	485.88	1,100.91
	Total Income	38,024.09	39,559.94	35,614.28	77,584.03	71,914.60	151,314.11
2	EXPENSES						
	a) Cost of Materials Consumed	19,637.69	19,140.85	19,687.69	38,778.54	39,051.82	76,157.11
	b) Purchases of Stock-in-Trade	2,000.32	165.45	-	2,165.77	1,400.98	1,375.98
	c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(3,655.86)	1,009.23	(610.61)	(2,646.63)	(2,539.45)	(2,336.12)
	d) Employee Benefits Expense	3,547.42	3,700.96	2,983.52	7,248.38	6,136.54	13,033.33
	e) Finance Costs	539.33	424.87	381.61	964.20	785.03	1,663.46
	f) Depreciation and Amortisation Expenses	1,889.28	1,829.27	1,631.63	3,718.54	3,175.32	6,601.38
	g) Other Expenses	7,722.61	6,966.71	6,173.92	14,689.32	12,324.58	27,367.04
	Total Expenses	31,680.79	33,237.34	30,247.76	64,918.13	60,334.81	123,862.19
3	Profit/(Loss) before Exceptional Items and Tax (1-2)	6,343.31	6,322.60	5,366.52	12,665.90	11,579.79	27,451.93
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before Tax (3-4)	6,343.31	6,322.60	5,366.52	12,665.90	11,579.79	27,451.93
6	TAX EXPENSES						
	a) Current Year Tax	1,279.47	1,156.68	1,036.00	2,436.15	2,136.00	4,912.00
	b) Earlier Year Tax	-	-	-	-	-	(306.27)
	c) Deferred Tax	280.27	451.48	150.00	731.75	500.00	2,781.65
	Total Tax Expenses	1,559.73	1,608.16	1,186.00	3,167.90	2,636.00	7,387.39
7	Net Profit/(Loss) from Ordinary Activities after Tax (5-6)	4,783.57	4,714.43	4,180.52	9,498.00	8,943.79	20,064.54
8	Exceptional Items	-	-	-	-	-	-
9	Net Profit/(Loss) for the period (7-8)	4,783.57	4,714.43	4,180.52	9,498.00	8,943.79	20,064.54
10	OTHER COMPREHENSIVE INCOME						
	a. Items that will be reclassified to Statement of Profit and Loss	(117.30)	(23.16)	(62.38)	(140.45)	54.29	13.31
	b. Items that will Not be reclassified to Statement of Profit and Loss	-	-	-	-	-	-
11	Total Comprehensive Income for the period (10+11)	4,666.27	4,691.28	4,118.14	9,357.55	8,998.08	20,077.85
12	Earnings per Equity share: - (Rs)						
	(1) Basic	5.28	5.20	4.61	10.48	9.87	22.14
	(2) Diluted	5.27	5.20	4.61	10.47	9.87	22.14
13	Paid-up Equity Share Capital (Face Value of Rs. 5/-each)	4,531.30	4,531.30	4,531.30	4,531.30	4,531.30	4,531.30
14	Reserve excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year						157,614.59
<p>1 The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).</p> <p>2 The above results for the quarter and half year ended 30th September 2024, have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 28th October, 2024.</p> <p>3 The Company has identified only one segment i.e. Pharmaceuticals</p> <p>4 The aforesaid financial results are available on the Company's website at www.aartipharmalabs.com and are also available on the website of BSE limited www.bseindia.com & the National Stock Exchange of India Limited www.nseindia.com</p> <p>5 Figures for the previous period have been regrouped or rearranged wherever necessary.</p>							
Place : Mumbai Date : 28th October, 2024		For AARTI PHARMALABS LIMITED  Hetal Gogri Gala Vice Chairperson & Managing Director					


AARTI PHARMALABS LIMITED
www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com
Factory : Unit - V, Plot No. L - 28/29, M.I.D.C., Tarapur, Taluka & District - Palghar, PIN 401 506, Maharashtra, INDIA, T : +91 77988 82264 / +91 70309 64131
Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED							
Consolidated Audited Financial Results for the Quarter & Half Year Ended 30th September, 2024							
(Rs in Lakhs except EPS)							
Sr. No.	Particulars	Consolidated Results					
		3 Months Ended			6 Months Ended		Year Ended
		30th Sept 2024 (Audited)	30th June 2024 (Audited)	30th Sept 2023 (Audited)	30th Sept 2024 (Audited)	30th Sept 2023 (Audited)	31st Mar 2024 (Audited)
1.00	INCOME						
	a) Revenue from Operations (Net)	45,802.58	55,549.34	43,980.00	101,351.93	89,814.69	185,260.62
	b) Other Income	448.28	221.62	98.49	669.90	147.00	489.50
	Total Income	46,250.87	55,770.96	44,078.49	102,021.83	89,961.69	185,750.12
2.00	EXPENSES						
	a) Cost of Materials Consumed	22,057.64	21,980.65	22,189.00	44,038.29	44,195.02	85,844.71
	b) Purchases of Stock-in-Trade	9,810.20	8,693.86	3,520.00	18,504.06	8,385.33	18,221.79
	c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(8,310.18)	3,149.62	(484.00)	(5,160.56)	(263.86)	(1,994.77)
	d) Employee Benefits Expense	3,772.97	3,923.37	3,160.00	7,696.34	6,484.87	13,840.74
	e) Finance Costs	550.56	483.31	389.00	1,033.87	806.20	1,721.47
	f) Depreciation and Amortisation Expenses	2,088.32	2,016.75	1,814.00	4,105.07	3,534.05	7,323.53
	g) Other Expenses	9,104.59	8,155.75	6,796.00	17,260.34	13,727.84	30,743.77
	Total Expenses	39,074.11	48,403.30	37,384.00	87,477.41	76,869.45	155,701.24
3.00	Profit/(Loss) before Exceptional Items and Tax (1-2)	7,176.76	7,367.66	6,694.49	14,544.42	13,092.24	30,048.88
4.00	Exceptional Items	-	-	-	-	-	-
5.00	Profit/(Loss) before Tax (3-4)	7,176.76	7,367.66	6,694.49	14,544.42	13,092.24	30,048.88
6.00	TAX EXPENSES*						
	a) Current Year Tax	1,444.47	1,416.68	1,401.60	2,861.15	2,753.75	5,883.75
	b) Earlier Year Tax	-	-	-	-	-	(306.27)
	c) Deferred Tax	270.04	405.63	112.60	675.67	449.51	2,781.51
	Total Tax Expenses	1,714.51	1,822.31	1,514.20	3,536.82	3,203.26	8,358.99
7.00	Net Profit/(Loss) from Ordinary Activities after Tax (5-6)	5,462.25	5,545.35	5,180.29	11,007.60	9,888.98	21,689.89
8.00	Exceptional Items (Net of Tax Expense)	-	-	-	-	-	-
9.00	Net Profit/(Loss) for the period (7-8)	5,462.25	5,545.35	5,180.29	11,007.60	9,888.98	21,689.89
10.00	Profit/(loss) for the period attributable to						
	a) Owners of the Company	5,462.25	5,545.35	5,180.29	11,007.60	9,888.98	21,689.89
	b) Non Controlling Interest	-	-	-	-	-	-
11.00	OTHER COMPREHENSIVE INCOME						
	a. Items that will be reclassified to Statement of Profit and Loss	(276.78)	48.34	(373.00)	(228.44)	15.00	(45.13)
	b. Items that will Not be reclassified to Statement of Profit and Loss	-	-	-	-	-	-
12.00	Total Comprehensive Income for the period (10+11)	5,185.47	5,593.69	4,807.29	10,779.16	9,903.98	21,644.76
13.00	Earnings per Equity share - (Rs)						
	(1) Basic	6.03	6.12	5.72	12.15	10.91	23.93
	(2) Diluted	6.02	6.12	5.72	12.14	10.91	23.93
14.00	Paid-up Equity Share Capital (Face Value of Rs. 5/-each)	4,531.30	4,531.30	4,531.30	4,531.30	4,531.30	4,531.30
15.00	Reserve excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year						171,172.62
<p>1 The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).</p> <p>2 The above results for the quarter and half year ended 30th September 2024, have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 28th October, 2024.</p> <p>3 The Company has identified only one segment i.e. Pharmaceuticals</p> <p>4 The aforesaid financial results are available on the Company's website at www.aartipharmalabs.com and are also available on the website of BSE limited www.bseindia.com & the National Stock Exchange of India Limited www.nseindia.com</p> <p>5 Figures for the previous period have been regrouped or rearranged wherever necessary.</p>							
Place : Mumbai Date : 28th October 2024		For AARTI PHARMALABS LIMITED  Hetal Gogri Gaha Vice Chairperson & Managing Director					


AARTI PHARMALABS LIMITED
www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com
Factory : Unit - V, Plot No. L - 28/29, M.I.D.C., Tarapur, Taluka & District - Palghar, PIN 401 506, Maharashtra, INDIA, T : +91 77988 82264 / +91 70309 64131
Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



AARTI PHARMALABS

AARTI PHARMALABS LIMITED				
Balance Sheet as at 30th September, 2024				
(Rs in Lakhs)				
Particulars	Standalone		Consolidated	
	As at 30th Sept, 2024	As at 31st March, 2024	As at 30th Sept, 2024	As at 31st March, 2024
A				
1.00 Non-Current Assets				
(a) Property, Plant and Equipment	101,670.44	91,600.17	109,445.75	99,421.98
(b) Capital Work-in-Progress	11,599.22	7,849.71	11,599.17	7,849.71
(c) Right to use Assets	1,789.87	2,047.17	1,789.87	2,047.17
(d) Goodwill			178.06	178.06
(e) Other Intangible Assets	2,663.57	1,685.55	2,668.26	1,685.44
(f) Intangible Assets Under Developments	6,327.73	5,841.96	6,327.73	5,841.96
(g) Financial Assets				
(i) Investments				
(a) Investment in Subsidiary & Joint Control	1,351.62	1,351.62	-	-
(b) Other Investments	3,056.77	3,031.53	3,580.52	3,677.96
(ii) Loan	715.58	585.23	715.58	585.23
(iii) Other Financial Assets	1,463.41	1,065.85	1,598.31	1,132.90
(h) Other Non-Current Assets	2,069.78	1,226.02	2,080.58	1,226.02
Total Non-Current Assets	132,708.00	116,284.82	139,983.84	123,646.43
2.00 Current Assets				
(a) Inventories	63,419.73	58,215.32	71,979.60	64,285.84
(b) Financial Assets				
(i) Investment	1,587.52	1,783.07	5,815.95	7,039.40
(i) Trade Receivables	38,733.28	44,882.30	43,340.58	51,934.44
(ii) Cash and Cash Equivalents	2,350.22	399.62	4,080.79	2,363.49
(iii) Bank Balance Other than (ii) above	54.57	43.09	54.57	43.09
(iv) Loans	71.31	92.57	97.69	125.11
(v) Other Financial Assets	461.67	628.19	461.67	628.20
(c) Other Current Assets	10,524.72	7,056.74	11,266.04	7,800.24
(d) Current Tax Assets (Net)	670.56	305.34	570.48	344.28
Total Current Assets	117,873.56	113,406.24	137,667.35	134,564.09
TOTAL ASSETS	250,581.56	229,691.06	277,651.19	258,210.51
B EQUITY AND LIABILITIES				
1.00 EQUITY				
(a) Equity Share Capital	4,531.30	4,531.30	4,531.30	4,531.30
(b) Other Equity	166,161.73	157,614.59	181,141.37	171,172.62
Total Equity	170,693.03	162,145.89	185,672.67	175,703.92
2.00 LIABILITIES				
Non-Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	10,152.04	-	10,155.95	3.88
(ii) Lease Liabilities	1,281.40	1,665.91	1,281.40	1,665.91
(iii) Provision	555.50	527.62	704.91	605.90
(b) Deferred Tax Liabilities (Net)	10,539.80	9,793.25	11,487.53	10,792.00
Total Non-Current Liabilities	22,528.73	11,986.78	23,629.80	13,067.69
Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	26,593.43	25,079.73	26,594.47	26,406.47
(i) Lease Liabilities	615.16	449.14	615.16	449.14
(ii) Trade Payables Due to				
- Micro and Small Enterprises	441.91	1,890.08	631.13	1,890.08
- Other Than Micro and Small Enterprises	22,165.05	23,588.44	32,721.52	35,941.61
(iii) Others Financial Liabilities	4,130.13	2,842.44	4,264.77	3,020.46
(b) Provisions	1,171.50	624.36	1,279.07	631.37
(c) Current Tax Liabilities (Net)	-	-	-	-
(d) Other Current Liabilities	2,242.62	1,084.18	2,242.62	1,099.77
Total Current Liabilities	57,359.79	55,558.38	68,348.73	69,438.90
Total Liabilities	79,888.52	67,545.17	91,978.53	82,506.59
TOTAL EQUITY AND LIABILITIES	250,581.56	229,691.06	277,651.19	258,210.51



AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Factory : Unit - V, Plot No. L - 28/29, M.I.D.C., Tarapur, Taluka & District - Palghar, PIN 401 506, Maharashtra, INDIA. T : +91 77988 82264 / +91 70309 64131

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED					
Cash Flow Statement for the Half Year Ended 30th September, 2024				(Rs in Lakhs)	
Sr. No.	Particulars	Standalone		Consolidated	
		For the Half Year Ended 30th September 2024	For the Half Year Ended 30th September 2023	For the Half Year Ended 30th September 2024	For the Half Year Ended 30th September 2023
A.	Cash Flow from Operating Activities:				
	Net Profit before Tax and Exceptional/Extraordinary Items	12,665.90	11,579.79	14,544.42	13,092.24
	<u>Adjustments for:</u>				
	Finance Costs	964.20	785.03	1,033.87	806.20
	Depreciation and Amortisation Expenses	3,718.54	3,175.32	4,105.07	3,534.05
	Dividend Income	(123.93)	(464.74)	(3.09)	-
	Interest income	(157.44)	-	(347.66)	(22.50)
	Profit on Sale of Assets/Investments	-	-	-	(39.00)
	R&D Project write off	259.00	-	259.00	-
	Provision for Bad and Doubtful Debts	15.65	-	15.65	-
	Realisation Gain/ (Loss) on forward contract/Miscellaneous	-	-	-	-
	Operating Profit before Working Capital Changes	17,341.93	15,075.39	19,607.26	17,370.99
	<u>Adjustments for:</u>				
	(Increase)/Decrease in Trade and Other Receivables	1,035.07	(1,463.40)	3,456.56	(710.00)
	(Increase)/Decrease in Inventories	(5,204.41)	(2,326.67)	(7,693.76)	(51.00)
	Increase/(Decrease) in Trade Payables and Other Current Liabilities	149.57	1,441.69	(1,344.79)	(1,892.69)
	Cash Generated from Operations	13,322.16	12,727.01	14,025.27	14,717.30
	Direct Taxes Paid	(2,686.15)	(2,843.59)	(2,861.15)	(3,044.00)
	Net Cash Flow from Operating Activities (A)	10,636.01	9,883.42	11,164.12	11,673.30
B.	Cash Flow from Investing Activities:				
	Addition to Property, Plant & Equipment/Capital WIP	(17,107.23)	(6,405.03)	(17,447.32)	(6,969.00)
	Investments under Intangible assets under Development	(1,637.57)	(2,117.07)	(1,642.26)	(2,117.00)
	(Increase)/Decrease in Other Investments	201.25	-	1,110.56	(665.00)
	Dividend Income	123.93	464.74	127.02	-
	Interest income	157.44	-	347.66	22.00
	Profit on Sale of Assets/Investments	-	(0.20)	-	-
	Net Cash Flow from Investing Activities (B)	(18,263.18)	(8,057.56)	(17,504.34)	(9,729.00)
C.	Cash Flow from Financing Activities:				
	Proceeds/(Repayment) from Non Current Borrowing (Net)	10,152.04	-	10,152.07	-
	Proceeds/(Repayment) from Current Borrowing (Net)	1,513.70	(331.84)	188.00	(1,005.50)
	Finance Costs	(883.21)	(731.00)	(952.88)	(752.80)
	Lease liability payment	(299.49)	(225.43)	(299.49)	(226.00)
	Dividend Paid	(906.26)	-	(1,030.19)	-
	Net Cash Flow from Financing Activities (C)	9,576.78	(1,288.27)	8,057.51	(1,984.30)
	Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	1,950.60	537.61	1,717.30	(40.00)
	Cash and Cash Equivalents (Opening Balance)	399.62	1,310.94	2,363.49	2,493.00
	Cash and Cash Equivalents (Closing Balance)	2,350.22	1,848.60	4,080.79	2,453.00

Place : Mumbai
Date : 28th October 2024



For AARTI PHARMALABS LIMITED

Hetal Gogri Gala
Vice Chairperson & Managing Director



AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Factory : Unit - V, Plot No. L - 28/29, M.I.D.C., Tarapur, Taluka & District - Palghar, PIN 401 506, Maharashtra, INDIA. T : +91 77988 82264 / +91 70309 64131

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



Independent Auditors' Report on Audit of Standalone Financial Results

To Board of Directors of
Aarti Pharmalabs Limited

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of Aarti Pharmalabs Limited ('the Company') for the quarter and period ended 30th September 2024 ('standalone financial results') attached herewith, being submitted by the Company pursuant to regulatory requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:


1. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
2. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of net profit and total other comprehensive income and other financial information of the Company for the quarter and period ended 30th September 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Managements and Board of Directors' Responsibilities for the Standalone Financial Results

These quarterly and year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Management and the Board of Directors are responsible for the preparation of these standalone financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.





This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.





- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

Uday Girjapure
Partner
Membership No. 161776
UDIN: 24161776BKFXQY4416
Date: 28th October 2024
Place: Mumbai





Independent Auditors' Report on Audit of Consolidated Financial Results

To Board of Directors of Aarti Pharmed Labs Limited
Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of Aarti Pharmed Labs Limited ('Holding Company'), its subsidiaries and joint controlled entity (Holding Company together with its subsidiaries and joint controlled entity 'the Group') for the quarter and period ended 30th September 2024 ('Consolidated financial results'), being submitted by the Holding Company pursuant to regulatory requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements / financial information of subsidiaries (refer other matter paras), the Statement:

1. includes the results of the following entities:
 - a. **Subsidiaries**
 - i. Aarti USA Inc
 - ii. Aarti Pharmachem Limited
 - b. **Joint Controlled Entity**
 - i. Ganesh Polychem Limited
2. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
3. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the Consolidated net profit and Consolidated total other comprehensive income and other financial information of the Group for the quarter and period ended 30th September 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.





Management's Responsibilities for the Consolidated Financial Results.

These quarterly and year to date Consolidated Financial Results have been prepared on the basis of the consolidated financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.





- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's Internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the Financial Results/financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in the section titled 'Other Matters' in this audit report.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.





Other Matters

I. Financial Results of components not audited by us.

- a) The consolidated financial results include the audited financial results of 1 subsidiary and 1 Jointly controlled entity whose financial Results reflect total assets of Rs. 18,753 Lakhs (before consolidation adjustments) as at 30th September 2024, total revenues of Rs. 3,133 Lakhs and Rs. 7,674 Lakhs (before consolidation adjustments) and total net profit after tax of Rs. 545 Lakhs and net profit after tax Rs.1,259 Lakhs (before consolidation adjustments) for the quarter and period ended 30th September 2024 and cash inflows (net) of Rs. 486 Lakhs (before consolidation adjustments) for the period ended 30th September 2024 respectively as considered in the consolidated financial results, which have been audited by their respective independent auditors. The independent auditors' reports on Financial Results of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- b) The consolidated financial results include the audited financial results of 1 foreign subsidiary whose financial Results/ financial information reflects total assets of Rs. 10,263 Lakhs (before consolidation adjustments) as at 30th September 2024, total revenues of Rs. 5,301 Lakhs and Rs. 17,092 Lakhs (before consolidation adjustments) and total net profit after tax of Rs. 119 Lakhs and net Profit after tax Rs.340 Lakhs (before consolidation adjustments) for the quarter and period ended 30th September 2024 and cash outflows (net) of Rs. 719 Lakhs (before consolidation adjustments) for the period ended 30th September 2024 respectively as considered in the consolidated financial results. These audited financial results have been furnished to us by the board of directors and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on such audited financial statements.

Our opinion is not modified in respect of the above matter.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W





Uday Girjapure
Partner
Membership No. 161776
UDIN: 24161776BKFXQZ7856
Date: 28th October 2024
Place: Mumbai